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BACKGROUND: Ozone as a strong oxidant may induce
an inflammatory response.
Aim: The hypothesis was verified as to whether
ozonated autohemotherapy using an ozone dose in
therapeutic range changes the plasma concentration
of C-reactive protein and interleukin-6, markers of
inflammation.
Methods: In a controlled, single-blind, cross-over
study, 12 chronically hemodialyzed patients with
peripheral arterial disease were exposed to nine
sessions of autohemotherapy with blood exposure
to oxygen as a control followed by nine sessions of
ozonated autohemotherapy with an ozone concen-
tration of 50 mg/ml.
Results: There was no statistical difference between
C-reactive protein levels at baseline (1.539 /1.01 mg/l),
after nine sessions of control autohemotherapy
(1.489 /0.96 mg/l), and after nine sessions of ozonated
autohemotherapy (1.559 /0.84 mg/l). There was also
no statistical difference between the interleukin-6
serum concentration at baseline (4389 /118 pg/ml),
after nine sessions of control autohemotherapy
(4449 /120 pg/ml), and after nine sessions of ozo-
nated autohemotherapy (4669 /152 pg/ml).
Conclusion: The results of this study suggest that
ozonated autohemotherapy using an ozone concen-
tration of 50 mg/ml does not induce an inflammatory
response.
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mation, C-reactive protein, Interleukin-6, Hemodialysis,
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Introduction
Major ozonated autohemotherapy constitutes a com-
plementary medical approach in the treatment of
different disease states (reviewed in 1,2). The main
criticism concerning this controversial therapy is
associated with the oxidative properties of ozone
and its potentially harmful influence on cells and
biological processes.
3 To gain more light into this
issue, we commenced the clinical project aimed
to check the safety of ozonated autohemotherapy
(O3-AHT) in the treatment of ischemic complaints in
hemodialyzed (HD) patients with peripheral arterial
disease. O3-AHT applied in the therapeutic dose
range according to Bocci’s recommendations has
been found not to cause either protein or lipid
oxidative modification.
4 Intravascular hemolysis, an-
other possible side effect, was also not observed in
the same study. We have also demonstrated that O3-
AHT does not have any deleterious effects on the
endothelium nor promotes platelet aggregation.
4,5
Other authors did not find any negative effects of
ozone on white blood cell or red blood cell
function.
6,7
In the present study, the influence of O3-AHT on
the inflammation process was evaluated in subjects
on dialysis maintenance. These patients are particu-
larly threatened by the development of inflammation.
Renal failure per se may contribute to the inflamma-
tion response, which enhances as renal function
declines, and is greatest still in patients on dialysis
(reviewed in 8,9). Inflammation is considered an
important non-traditional cardiovascular risk factor.
Given that HD patients are at increased risk for
cardiovascular complications, one has no doubt that
any intervention that may potentially induce inflam-
matory response in these subjects needs particular
attention.
Patients and methods
Subjects
Twelve chronically HD patients were enrolled to the
study. They underwent regular bicarbonate HD
treatment, three times per week. Their detailed
characteristic have been presented elsewhere.
10,11
All of them suffered from symptomatic peripheral
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377arterial disease (stage II /III according to Fontain),
which was the main reason for the implementation of
O3-AHT. The HD prescription, namely dialyzer
type, HD session length, rate of dialysis solution
and blood flow, as well as any pharmacological
treatment, were unchanged during the study and 2
months prior to the study commencement. Indivi-
duals with active chronic inflammatory disease and
those with symptomatic or asymptomatic (as con-
firmed by laboratory tests; C-reactive protein [CRP]
evaluation) acute infection were excluded from the
study.
Study design
At the beginning subjects received nine sessions
of autohemotherapy with blood exposure to medical
oxygen (AHT) as a control, followed by nine sessions
of O3-AHT. The procedures were performed three
times a week in the early morning, just before the
HD session, in a single blind manner. An ozone
generator (ATO-3; Kriometrum, Warsaw, Poland)
attested by the Polish Health Ministry was used in
the study. The procedure of O3-AHT has been
described elsewhere in detail.
4,10,11 During O3-AHT
sessions, 250 ml of the patients’ blood was exposed
ex vivo to an oxygen /ozone mixture with an ozone
concentration of 50 mg/ml. Three blood samples were
collected from all subjects at the following
time-points: before the first session of AHT (first
collection), after the ninth session of AHT (second
collection */ control) and after the ninth session of
O3-AHT (third collection).
Interleukin-6 bioassay
Interleukin (IL)-6 levels in the sera were determined
using the B9 hybrydoma proliferation assay.
12 In this
assay, 10  /10
3 B9 cells (a gift from Dr L. Aarden,
Netherland Red Cross, Amsterdam, The Netherlands)
were cultured on a 96-well plate (NUNC
TM; Roskilde,
Denmark) with 50 times diluted samples of sera or
supernatants in the final volume of 100 ml of RPMI
1640 (Gibco BRL, Life Technologies, Inc., Gaithers-
burg, MD, USA), supplemented with 5  /10
 5 Mo f2 -
mercaptoethanol (Sigma, Mannheim, Germany), 10%
fetal calf serum (Gibco BRL, Life Technologies, Inc.),
100U/ml of penicilin and 100 mg/ml of streptomycin
(Sigma). All samples were put on a 96-well plate in
triplicate. After 48 h of incubation in a humidified
atmosphere containing 5% CO2 at 378C, 20 ml of MTT
(Sigma) were added to each well of the plate. The
plate was incubated for the next 4 h in the afore-
mentioned conditions, and after this time 100 mlo f
isopropanol (Sigma) were added. The optical density
was read at 570 nm on the automated plate reader
(Bio-Tek FL600; Bio-Tek Instruments, Inc. Winooski,
Vermont, USA). A standard curve relating cell pro-
liferation to doses of recombinant human IL-6
(Sigma) was used to quantify IL-6 activity in the
samples.
To confirm the specificity of the test, the mono-
clonal anti-IL-6 antibody (Genzyme, Ru ¨sselsheim,
Germany) was added (1:10, 1:20, 1:50) to the
samples. The anti-IL-6 monoclonal antibody comple-
tely inhibited the ability of the B9 cells to proliferate.
This assay had a detection limit of 1 pg/ml. The inter-
assay coefficient of variation ranged between 9.5%
and 10.9%. The inter-assay coefficient of variation
ranged between 15.2% and 17.7%.
Serum concentrations of IL-6 were assessed using a
specific sandwich enzyme-linked immunosorbent
assay by R&D Systems, Minneapolis, MN, USA. All
samples were analyzed in triplicate. The amount of
cross-reactivity was assessed by comparison with the
concentration yielding a 50% inhibition of binding.
Sensitivity levels were between 0.3 and 3000 pg/ml
(IL-6); intra-assay and inter-assay precision variability
was B /3% (controls, data not shown). Enzyme-linked
immunosorbent assay antibodies against IL-6 were
used to absorb the cytokines from cell culture
supernatants or sera.
CRP assay
CRP plasma level analysis was performed immuno-
turbidimetrically using a commercially available kit
(Tina-quant CRP; Boehringer Mannheim, Germany)
according to the manufacturer’s instruction.
Statistical analysis
Data are expressed as means9 /standard deviations.
Differences of variables were assessed by analysis of
variance for repeated measurements. Data were
evaluated using the STATISTICA software package
(version 6.0; StatSoft Inc., Tulsa, OK, USA).
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FIG. 1. CRP and IL-6 plasma concentrations after control
autohemotherapy and after ozonated autohemotherapy
(O3-AHT).
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All of 12 patients who entered the study completed
the protocol. During the study no patient demon-
strated symptoms of acute infectious disease.
The CRP serum level, analyzed as a marker of
inflammation, was in the normal range through-
out the study in all patients (0 /9 mg/l). There
were no statistical differences between CRP levels
at baseline (1.539 /1.01 mg/l), after nine sessions
of control AHT (1.489 /0.96 mg/l), and after nine
sessions of O3-AHT (1.559 /0.84 mg/l). There was
also no statistical difference between IL-6 serum
concentrations at baseline (438   /118 pg/ml),
after nine sessions of control AHT (4449 /120 pg/
ml), and after nine sessions of O3-AHT (4669 /152
pg/ml).
Discussion
The investigation of systemic inflammation has been
intensive in recent years, as it has been clearly shown
that even low-level inflammation may be responsible
for increased risk for cardiovascular disease in
individuals with as well as without renal failure.
13
Markers of inflammation such as CRP and IL-6
powerfully predict death from all causes and from
cardiovascular disease.
14 The underlying mechanisms
of such deleterious consequences of inflammation
involve vascular injury and malnutrition. It has been
clearly demonstrated that inflammation, by suppres-
sing synthesis or increasing catabolic rates of albu-
min, transferrin, and other negative acute-phase
proteins, either combines with modest malnutrition
or mimics malnutrition. More importantly, inflamma-
tion alters protein composition and endothelial
structure and function so as to promote vascular
disease.
8,9
The generation of oxygen free radicals is known to
be involved in the development of the systemic
inflammatory response. In addition to their actions
as noxious mediators generated by inflammatory
cells, these molecules also play a crucial role
contributing to the onset and progression of inflam-
mation in distant organs. In the early stages of the
inflammation process, free radicals exert their actions
via activation of nuclear factors, such as nuclear
factor-kappa-b or activator protein-1, that induce the
synthesis of cytokines.
15 The fact that ozone dissol-
ving in blood generates the production of free
radicals such as hydrogen peroxide
3 forms the back-
ground for the hypothesis that O3-AHT may also
promote the inflammation.
The previous in vitro studies demonstrated that
ozone induced secretion of proinflammatory cyto-
kine IL-6 from human macrophages and lympho-
cytes.
16,17 Otherwise, there is no clinical studies on
this point with respect to therapeutic use of ozone.
To examine the effects of O3-AHT on in vivo
inflammatory response, the CRP and IL-6 plasma
concentrations were measured before and after nine
sessions of O3-AHT in the study, using autohe-
motherapy along with oxygen exposure as a control.
CRP, a short-lived acute-phase protein, was used as a
non-specific but very sensitive marker of inflamma-
tion. We also analyzed plasma level of IL-6, a
pleiotropic proinflammary cytokine that induces the
synthesis of CRP in hepatocytes.
14 The study clearly
demonstrated that neither the CRP nor IL-6 levels
changed after O3-AHT. The plasma concentration of
CRP and IL-6 measured after nine sessions of O3-AHT
did not differ from the CRP and IL-6 levels assessed
after control AHT (Fig. 1). To our best knowledge,
this is the first clinical study concerning the influence
of O3-AHT on markers of inflammation. Given our
results, one may conclude that O3-AHT in a dose of
50 mg of ozone/ml of ozone /oxygen mixture did not
induce an inflammatory response. One may hypothe-
size that it might be a consequence of the relatively
low dose of ozone, which has previously been
shown not to cause oxidative injuries in HD pa-
tients.
11 The possibility cannot be excluded that
ozone-induced inflammation is attenuated with mul-
tiday exposure.
18 The results of this study seem to
further confirm the safety of O3-AHT treatment in
patients chronically treated with HD.
References
1. Bocci V. Oxygen /Ozone Therapy. A Critical Evaluation, Dordrecht:
Kluwer Academic Publishers, 2002.
2. Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. Int J Artif Organs 2004;
27: 168 /175.
3. Ueno I, Hoshino M, Miura T, Shinriki N. Ozone exposure generates free
radicals in the blood samples in vitro. Detection by the ESR spin-
trapping technique. Free Radic Res 1998; 29:1 2 7 /135.
4. Tylicki L, Biedunkiewicz B, Nieweglowski T, et al. Ozonated auto-
hemotherapy in patients on maintenance hemodialysis: inﬂuence on
lipid proﬁle and endothelium. Artif Organs 2004; 28:2 3 4 /237.
5. Tylicki L, Lizakowski S, Biedunkiewicz B, et al. Platelet function
unaffected by ozonated autohemotherapy in chronically hemodialyzed
patients. Blood Coagul Fibrinolysis 2004; 15:6 1 9 /622.
6. Zimran A, Wasser G, Forman L, Gelbart T, Beutler E. Effect of ozone on
red blood cell enzymes and intermediates. Acta Haematol 2000; 102:
148 /151.
7. Margalit M, Attias E, Attias D, Elstein D, Zimran A, Matzner Y. Effect of
ozone on neutrophil function in vitro. Clin Lab Haematol 2001; 23:
243 /247.
8. Kaysen GA, Eiserich JP. Characteristics and effects of inﬂammation in
end-stage renal disease. Semin Dial 2003; 16:4 3 8 /446.
9. Galle J, Seibold S, Wanner C. Inﬂammation in uremic patients: what is
the link? Kidney Blood Press Res 2003; 26:6 5  /75.
10. Tylicki L, Biedunkiewicz B, Nieweglowski T, et al. Fistula function and
dialysis adequacy during ozonotherapy in chronically dialyzed patients.
Artif Organs 2004; 28: 515 /519.
11. Tylicki L, Nieweglowski T, Biedunkiewicz B, et al. The inﬂuence of
ozonated autohemotherapy on oxidative stress in hemodialyzed patients
with atherosclerotic ischemia of lower limbs. Int J Artif Organs 2003; 26:
297 /303.
12. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM. Production of
hybridoma growth factor by human monocytes. Eur J Immunol 1987;
17: 1411 /1416.
13. Willerson JT, Ridker PM. Inﬂammation as a cardiovascular risk factor.
Circulation 2004; 109: II2 /II10.
Ozonated autohemotherapy on inflammation
Mediators of Inflammation Vol 13  2004 37914. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P.
C-reactive protein and interleukin-6 in vascular disease: culprits or
passive bystanders? J Hypertens 2003; 21: 1787 /1803.
15. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inﬂamma-
tory response. IUBMB Life 2004; 56: 185 /191.
16. Becker S, Quay J, Koren HS. Effect of ozone on immunoglobulin
production by human B cells in vitro. J Toxicol Environ Health 1991; 34:
353 /366.
17. Arsalane K, Gosset P, Vanhee D, et al. Ozone stimulates synthesis of
inﬂammatory cytokines by alveolar macrophages in vitro. Am J Respir
Cell Mol Biol 1995; 13:6 0 /68.
18. Christian DL, Chen LL, Scannell CH, Ferrando RE, Welch BS, Balmes JR.
Ozone-induced inﬂammation is attenuated with multiday exposure. Am
J Respir Crit Care Med 1998; 158: 532 /537.
Received 26 July 2004
Accepted 25 August 2004
L. Tylicki et al.
380 Mediators of Inflammation Vol 13  2004